药品注册申请号:021231
申请类型:NDA (新药申请)
申请人:ASTRAZENECA
申请人全名:ASTRAZENECA PHARMACEUTICALS LP
产品信息
产品号商品名活性成分剂型/给药途径规格/剂量参比药物(RLD)生物等效参考标准(RS)治疗等效代码该申请号批准日期该产品号批准日期市场状态
001 ZOMIG-ZMT ZOLMITRIPTAN TABLET, ORALLY DISINTEGRATING;ORAL 2.5MG Yes No AB 2001/02/13 2001/02/13 Discontinued
002 ZOMIG-ZMT ZOLMITRIPTAN TABLET, ORALLY DISINTEGRATING;ORAL 5MG Yes No AB 2001/09/17 Discontinued
批准日期,申请提交历史,通知信,药品说明书,审评文件等信息
提交状态日期提交号审批结论申请内容分类审评优先级;罕用药状态通知信、审评文件、说明书、包装标签备注
2018/12/21 SUPPL-14(补充) Approval Labeling STANDARD
2012/09/14 SUPPL-11(补充) Approval Labeling UNKNOWN
2012/09/14 SUPPL-10(补充) Approval Labeling STANDARD
2010/08/11 SUPPL-9(补充) Approval Labeling STANDARD
2004/01/08 SUPPL-5(补充) Approval Labeling STANDARD
2003/05/21 SUPPL-4(补充) Approval Labeling STANDARD
2002/10/09 SUPPL-3(补充) Approval Labeling STANDARD
2001/12/04 SUPPL-2(补充) Approval Manufacturing (CMC) STANDARD
2001/09/17 SUPPL-1(补充) Approval Manufacturing (CMC) STANDARD
2001/02/13 ORIG-1(原始申请) Approval Type 3 - New Dosage Form STANDARD
与本品相关的专利信息(来自FDA橙皮书Orange Book)
关联产品号专利号专利过期日是否物质专利是否产品专利专利用途代码撤销请求提交日期专利下载备注
001 5466699 2012/11/14 PDF格式**本条是由Drugfuture回溯的历史信息**
5466699*PED 2013/05/14 PDF格式**本条是由Drugfuture回溯的历史信息**
002 5466699 2012/11/14 PDF格式**本条是由Drugfuture回溯的历史信息**
5466699*PED 2013/05/14 PDF格式**本条是由Drugfuture回溯的历史信息**
与本品相关的市场独占权保护信息
关联产品号独占权代码失效日期备注
与本品治疗等效的药品
活性成分:ZOLMITRIPTAN 剂型/给药途径:TABLET, ORALLY DISINTEGRATING;ORAL 规格:2.5MG 治疗等效代码:AB
申请号产品号申请类型商品名活性成分剂型/给药途径规格市场状态RLDRSTE Code产品号批准日期申请人
021231 001 NDA ZOMIG-ZMT ZOLMITRIPTAN TABLET, ORALLY DISINTEGRATING;ORAL 2.5MG Discontinued Yes No AB 2001/02/13 ASTRAZENECA
202560 001 ANDA ZOLMITRIPTAN ZOLMITRIPTAN TABLET, ORALLY DISINTEGRATING;ORAL 2.5MG Prescription No No AB 2013/05/14 GLENMARK PHARMS LTD
202890 001 ANDA ZOLMITRIPTAN ZOLMITRIPTAN TABLET, ORALLY DISINTEGRATING;ORAL 2.5MG Prescription No No AB 2013/05/15 ZYDUS PHARMS USA INC
202956 001 ANDA ZOLMITRIPTAN ZOLMITRIPTAN TABLET, ORALLY DISINTEGRATING;ORAL 2.5MG Prescription No No AB 2015/09/17 JUBILANT GENERICS
205074 001 ANDA ZOLMITRIPTAN ZOLMITRIPTAN TABLET, ORALLY DISINTEGRATING;ORAL 2.5MG Prescription No No AB 2016/12/01 ALEMBIC
活性成分:ZOLMITRIPTAN 剂型/给药途径:TABLET, ORALLY DISINTEGRATING;ORAL 规格:5MG 治疗等效代码:AB
申请号产品号申请类型商品名活性成分剂型/给药途径规格市场状态RLDRSTE Code产品号批准日期申请人
021231 002 NDA ZOMIG-ZMT ZOLMITRIPTAN TABLET, ORALLY DISINTEGRATING;ORAL 5MG Discontinued Yes No AB 2001/09/17 ASTRAZENECA
202560 002 ANDA ZOLMITRIPTAN ZOLMITRIPTAN TABLET, ORALLY DISINTEGRATING;ORAL 5MG Prescription No No AB 2013/05/14 GLENMARK PHARMS LTD
202890 002 ANDA ZOLMITRIPTAN ZOLMITRIPTAN TABLET, ORALLY DISINTEGRATING;ORAL 5MG Prescription No Yes AB 2013/05/15 ZYDUS PHARMS USA INC
202956 002 ANDA ZOLMITRIPTAN ZOLMITRIPTAN TABLET, ORALLY DISINTEGRATING;ORAL 5MG Prescription No No AB 2015/09/17 JUBILANT GENERICS
205074 002 ANDA ZOLMITRIPTAN ZOLMITRIPTAN TABLET, ORALLY DISINTEGRATING;ORAL 5MG Prescription No No AB 2016/12/01 ALEMBIC
更多信息
药品NDC数据与药品包装、标签说明书
©2006-2024 DrugFuture->U.S. FDA Drugs Database